Abstract
Background
Though umbilical cord bilirubin and hemoglobin cutoff values recommending exchange transfusion are available for neonates with ABO or Rh incompatibility, those for phototherapy are not.
Objective
To determine the predictive accuracy of cord bilirubin and hemoglobin for hyperbilirubinemia requiring phototherapy within the first 5 days of life among neonates with ABO and Rh incompatibility.
Methodology
Study Design
A prospective observational study was conducted from January 2022 to December 2022.
Study Participants
Neonates with Rh or ABO incompatibility
Intervention
The study participants were observed for hyperbilirubinemia requiring phototherapy within the first 5 days.
Outcome
The receiver operating characteristic (ROC) curve was plotted to determine the cutoff value of cord bilirubin and hemoglobin for predicting the need for phototherapy.
Results
Out of the 416 analyzed, 53.8% (n = 224) of the babies required phototherapy. ROC curve analysis showed umbilical cord bilirubin as a moderate predictor in determining the need for phototherapy, with an area under the curve (AUC) of 0.74 (95% CI: 0.69-0.79). The cutoff value of >2.25 mg/dL for cord bilirubin had a sensitivity of 75% and a specificity of 60%. A cord bilirubin value of 1.95 mg/dL had 90% sensitivity, and a value of 3.25 mg/dL had 100% specificity in predicting the need for phototherapy. Cord hemoglobin was not a good predictor for determining the need for phototherapy.
Conclusion
Though cord hemoglobin is a poor predictor in determining the development of significant hyperbilirubinemia requiring phototherapy in neonates with ABO and Rh setup, a cord bilirubin value above 2.25 mg/dL can be used as a cutoff for the same.
Get full access to this article
View all access options for this article.